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Abstract: OBJECTIVE Prognostic value of health-related quality of life (HRQoL) data may be important
to inform patients in clinical practice and to guide clinical decision-making. Our study investigated the
added prognostic value of HRQoL for overall survival (OS) and progression-free survival (PFS) in a large
heterogeneous sample of glioma patients, besides known prognostic factors. METHODS We included
individual baseline data from previously published randomised controlled trials (RCTs) in glioma patients
in which HRQoL was assessed through the European Organisation for Research and Treatment of Cancer
QLQ-C30 and QLQ-BN20 questionnaires. Multivariable Cox regression models (stratified for newly
diagnosed versus recurrent disease) were constructed, first with clinical variables (age, sex, tumour type,
performance status, allocated treatment and extent of resection) only and subsequently with HRQoL
variables added, separately for OS and PFS. The added prognostic value of HRQoL was calculated
using C-indices. RESULTS Baseline HRQoL and clinical data from 15 RCTs were included, comprising
5217 patients. In the model including both clinical and HRQoL variables, better cognitive and role
functioning and less motor dysfunction were independently associated with longer OS, whereas better
role and cognitive functioning, less nausea and vomiting and more appetite loss were independently
associated with prolonged PFS. However, C-indices indicated only a small prognostic improvement of
the models for OS and PFS when adding HRQoL to the clinical prognostic variables (+1.1% for OS
and +.7% for PFS). CONCLUSION Our findings demonstrate that several baseline HRQoL variables are
independently prognostic for OS and PFS, yet the added value of HRQoL to the known clinical prognostic
variables was small.
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Objective: Prognostic value of health-related quality of life (HRQoL) data may be important to inform 
patients in clinical practice and to guide clinical decision-making. Our study investigated the added 
prognostic value of HRQoL for overall survival (OS) and progression-free survival (PFS) in a large 
heterogeneous sample of glioma patients, besides known prognostic factors.  
Methods: We included individual baseline data from previously published randomized controlled 
trials (RCTs) in glioma patients in which HRQoL was assessed through the EORTC QLQ-C30 and QLQ-
BN20 questionnaires. Multivariable Cox regression models (stratified for newly-diagnosed versus 
recurrent disease) were constructed, first with clinical variables (age, sex, tumor type, performance 
status, allocated treatment and extent of resection) only, and subsequently with HRQoL variables 
added, separately for OS and PFS. The added prognostic value of HRQoL was calculated using C-
indices. 
Results: Baseline HRQoL and clinical data from 15 RCTs were included, comprising 5217 patients. In 
the model including both clinical and HRQoL variables, better cognitive and role functioning and less 
motor dysfunction were independently associated with longer OS, whereas better role and cognitive 
functioning, less nausea and vomiting and more appetite loss were independently associated with 
prolonged PFS. However, C-indices indicated only a small prognostic improvement of the models for 
OS and PFS when adding HRQoL to the clinical prognostic variables (+1.1% for OS and +0.7% for PFS).  
Conclusion: Our findings demonstrate that several baseline HRQoL variables are independently 









Health-related quality of life (HRQoL) is an important endpoint, both in clinical practice and in clinical 
trials in oncology. In clinical trials, HRQoL data may contribute to determine the net clinical benefit of 
a treatment strategy. In clinical practice, HRQoL data may provide important information on the 
patients’ functioning during the course of disease, and guide tailored treatment.1,2 This is particularly 
important in patient populations where survival is relatively short and where cure is not possible. 
HRQoL is therefore relevant for patients with gliomas, the most common malignant primary brain 
tumor in adults3. 
One important feature of HRQoL data may be its potential prognostic value for survival. 
Clinical variables such as age and performance status have proven to be important prognostic factors 
for overall survival (OS) in glioma patients, and recent studies have shown that HRQoL is an 
independent prognostic marker for survival in various other cancer populations4-6. If demonstrated to 
be an independent prognostic factor in glioma, HRQoL data could be used in clinical practice to inform 
patients, facilitate decision-making and ultimately to improve outcomes. In addition, HRQoL could be 
used as a stratification variable in future clinical trials7.  
The few studies that have investigated HRQoL as a prognostic factor for survival in glioma 
patients reported disparate results8-10; in glioblastoma and anaplastic oligodendroglioma patients, the 
specific HRQoL scales that were found to be of prognostic importance differed between studies, and 
the predictive ability of the models showed only modest improvement when adding HRQoL scales to 
known clinical predictors8,9. These findings may, in part, reflect methodological issues such as small 
sample sizes, missing baseline data, and statistical techniques chosen to analyze the data. Moreover, 
prognostic models in glioma research focused on OS as endpoint. In glioma, progression-free survival 
(PFS) may also be a relevant outcome, which can be seen as a surrogate endpoint for measuring 
treatment efficacy11. With this knowledge, it seems most appropriate to assess the prognostic value 





classification of tumor types involving molecular markers12,13. The added prognostic value of HRQoL 
in such a model has not yet been investigated. 
The aim of the present study was to investigate the added prognostic value of HRQoL for OS 





This study is part of the CODAGLIO (i.e. COmbining clinical trial DAtasets in GLIOma) project, in which 
a database was created including HRQoL data of individual glioma patients from 15 previously 
published phase II and III randomized controlled trials (RCTs) (see supplementary Table 1 for an 
overview). RCTs that assessed HRQoL with the European Organization for Research and Treatment of 
Cancer (EORTC) questionnaires were selected for inclusion. All patients gave their informed consent 
to participate in the RCTs, and all principal investigators of these RCTs gave permission for use of the 
collected data. In all RCTs, HRQoL was assessed as a secondary endpoint. 
 
HRQoL assessment 
HRQoL data in the included trials were assessed with the EORTC QLQ-C30 version 3.014, in conjunction 
with the EORTC brain cancer-specific QLQ-BN2015. The EORTC QLQ-C30 is the core EORTC 
questionnaire that includes 30 items, comprising five functioning scales (physical, role, emotional, 
cognitive and social functioning), three symptom scales (fatigue, pain, and nausea and vomiting), a 
global health status scale, and six single items (dyspnea, appetite loss, insomnia, constipation, 
diarrhea, and financial difficulties). The QLQ-BN20 was specifically designed for brain tumor patients 
and consists of 20 items, comprising four symptom scales (future uncertainty, visual disorder, motor 





loss, itchy skin, weakness of legs and bladder control)16. For both questionnaires, raw scores were 
linearly transformed to a scale from 0 to 100 according to the standard EORTC guidelines17. For the 
functioning scales and the global health status scale, a higher score indicates better functioning. For 
the symptom scales and single items, higher scores indicate more symptoms and worse functioning. 
In all RCTs, baseline questionnaires were administered before the start of the allocated treatment, 
but after surgery and irrespective of supportive treatment such as anti-epileptic drugs (AEDs) and 
corticosteroids.  
 
Other prognostic variables 
Sociodemographic and clinical variables previously recognized as prognostic for OS that were available 
in all included RCTs were collected: tumor type (WHO grade II or III astrocytoma, oligodendroglioma, 
and oligoastrocytoma (all classified as non-glioblastoma), or grade IV (glioblastoma)), age, sex, disease 
stage (newly-diagnosed versus recurrent), WHO performance status (PS) (0 versus 1 versus 2), prior 
resection (yes versus no), and allocated treatment (radiotherapy (RT monotherapy), chemotherapy 
(chemo monotherapy), angiogenesis inhibitors (angio monotherapy), tumor-treating fields (TTF 
monotherapy), radiotherapy and chemotherapy combined (RT and chemo), radio and angiogenesis 
inhibitors combined (RT and angio), radiotherapy combined with chemotherapy and angiogenesis 
inhibitors (RT and chemo and angio) and chemotherapy and TFF combined (chemo and TTF)). Prior 
resection was classified into yes/no, because information on the extent of resection (biopsy, partial 
or gross total resection) was not available for all patients. Therefore, we classified both partial and 
complete resection as resected, and biopsy as not resected. Due to the variety of treatments that 
were used in the different RCTs, treatments were categorized based on type and combination (e.g., 
lomustine, irinotecan, combined procarbazine, lomustine and vincristine (PCV) and temozolomide 





Although prognostic for survival, data on use of corticosteroids at baseline (yes/no) and data 
on use of AEDs at baseline (yes/no) were not available for all patients. To analyze the added prognostic 
value of HRQoL in a model including these factors, we conducted a subgroup analysis in the group of 
patients with available data for these variables. Likewise, data on molecular parameters were also 
only available for a selection of the patients (i.e. in more recent RCTs): isocitrate dehydrogenase (IDH) 
mutations (30%), co-deletion of chromosomal arms 1p and 19q (35%), and O6-methylguanine-DNA 
methyltransferase (MGMT) promotor methylation (64%). Therefore, another subgroup analysis was 
performed in patients with information on the molecular parameters IDH and 1p/19q, which allowed 
reclassification of tumor type following the 2016 WHO classification12. MGMT status was also included 
in this analysis (MGMT-methylated versus MGMT-unmethylated versus MGMT status unknown). 
 
Statistical analysis 
All patients with a completed baseline HRQoL form were included in the analyses. OS was measured 
from the date of randomization until the date of death (i.e. event), or the date of last contact 
(determined at the time of the database lock, separately for each individual RCT; i.e. censored 
patients), and was estimated using the Kaplan-Meier method. PFS was measured from the date of 
randomization until the date of progression or death (i.e. events), or date of last contact (determined 
at the time of the database lock, separately for each individual RCT; i.e. censored patients). In all 
included RCTs, progression was defined by means of the Response Assessment in Neuro-Oncology 
Criteria (RANO) or MacDonald criteria18,19. The log-rank test was used to compare survival 
distributions. To evaluate if there were differences between patients with and without a HRQoL form 
(i.e., selection bias), several clinical characteristics were compared using the Chi-square test for 
categorical data and independent Student’s t-tests for continuously distributed variables.  
The construction of the final prognostic models was based on two steps. First, univariable Cox 





independent variable (tumor type, age, sex, prior resection, WHO performance status and all HRQoL 
scales/items) and OS and PFS. Hazard ratios (HRs) and their corresponding 95% two-sided confidence 
intervals (CI) were calculated20. Subsequently, multivariable CPH models, separately for OS and PFS, 
were constructed, including those variables that exhibited P<.10 in univariable analysis. The models 
were stratified for disease stage (newly-diagnosed versus recurrent). First, proportional hazard 
assumptions for the Cox models were assessed graphically, and potential multicollinearity was 
investigated with Spearman-rank correlation coefficients. Next, a stepwise backward model was 
applied to eliminate non-significant parameters, with a criterion of P<0.05 for inclusion and a criteria 
of P>0.10 for exclusion. The model was first carried out with the sociodemographic/clinical variables 
only (‘clinical model’), and subsequently with the sociodemographic/clinical variables and HRQoL 
scales (‘clinical + HRQoL model’). The purpose of this second model was to assess the potential benefit 
of adding baseline HRQoL scores to the sociodemographic/clinical factors to predict survival more 
accurately. Performance of the two final multivariable models (one for OS and one for PFS) was 
assessed with Harrell’s concordance-index (C-index)21, which estimates the probability of concordance 
between predicted and observed responses. Finally, internal validation of the models was carried out 
by comparing the C-indices of 1000 bootstrap replications to correct for optimism22.  
Lastly, these steps were repeated in subgroups of patients, both for the subgroup with data 
on AEDs and corticosteroids, and for the subgroup with data on the molecular markers. Analyses were 
performed using IBM SPSS, version 23.023, while the calculation of C-indices and the validation of the 
models were performed with R24 using the rms package25. 
 
Results 
Individual patient data were obtained from 15 international RCTs including a total of 6048 patients 







Data collection and baseline characteristics  
Sociodemographic and clinical characteristics of the patients included in the RCTs are summarized in 
Table 1. Baseline HRQoL data were available for 86% (5217/6084) of the patients. Patients who 
completed a baseline HRQoL questionnaire were younger (mean age 53 versus 55 years), had a better 
WHO PS (WHO=0 in 38% versus 29%) and had undergone resection more often (74% versus 62%) than 
patients who did not complete the baseline HRQoL assessment. There was also a significant difference 
in survival time: patients who completed a HRQoL baseline form had longer OS than patients without 
a baseline form (median 18.0 months, 95% CI [17.3-18.7] versus median 14.7 months, 95% CI [13.3-
16.1], p<.001). Similarly for PFS, patients with a baseline form had longer PFS than patients without a 
baseline form (8.3 months, 95% CI [7.9-8.7] versus 5.3 months, 95% CI [4.7-5.9], p<.001). 
 
Univariable analyses 
Results of the univariable analyses showed that female sex, a younger age, non-glioblastoma tumor 
type, a better WHO PS, newly diagnosed tumor type, resection and treatment with radiotherapy alone 
were associated with longer OS and PFS (Table 2). Moreover, better scores on all baseline HRQoL 
functioning scales were associated with longer OS and PFS, except for emotional functioning, which 
was not significantly associated with longer PFS. Furthermore, lower baseline scores on most 
symptoms scales were associated with longer OS and PFS, except for pain, insomnia, diarrhea, 
headache, seizures and itchy skin that were not prognostic for either OS or PFS, and hair loss not for 
PFS (Table 2). 
 
Clinical model 
In the multivariable models for OS and PFS including the clinical variables only, female sex, a younger 





radiotherapy alone were independently associated with a longer OS and PFS (Table 3 and Table 4 
respectively).  
 
Clinical and HRQoL model 
In the multivariable models including both the clinical and HRQoL variables, all clinical variables 
remained significantly prognostic for OS and PFS. Among the HRQoL variables, better role and 
cognitive functioning and less motor dysfunction were associated with longer OS (Table 3), and better 




The validated C-index for the model predicting OS with both the clinical and HRQoL variables was 
reasonable, and similar in predicting survival to the model with the clinical variables only (C=.721 
versus C=.716, respectively) (Table 5). This represents a relative gain in predictive accuracy of 1.1% 
(see Table 5 for the calculation). Similar results were found for PFS, with predictive abilities of C=.683 
and C=.679 for the clinical model and clinical + HRQoL model, respectively. The added value of the 
HRQoL scales in this model was also small (0.7%, Table 5).  
 
Subgroup analysis: AEDs and corticosteroids  
Baseline data on AEDs and corticosteroid use were available for 48% of the patients. Besides the 
clinical variables, only the none-use of corticosteroids at baseline was found to be prognostic for 
longer OS in both the clinical and clinical + HRQoL model, whereas the (none-)use of AEDs was not 
(supplementary table 2). Among the HRQoL variables, lower levels of fatigue and motor dysfunction 
were prognostic for longer OS and better role functioning, less appetite loss and weakness of the legs 





presence of the clinical variables and AEDs and corticosteroid use after validation was small: 0.5% for 
OS and -0.2% for PFS, with similar C-indices as for the ‘original model’(Table 5). 
 
Subgroup analysis: WHO 2016 classification and MGMT status 
When constructing a model including the WHO 2016 tumor classification and MGMT status, 35% of 
patients (maximum n=1748) were available for the analysis. In the model with both the clinical and 
HRQoL variables, female sex, younger age, a better WHO PS, MGMT-methylation, worse emotional 
functioning, less fatigue, and less nausea and vomiting were prognostic for longer OS (supplementary 
table 3). For PFS, the same clinical variables except sex were prognostic for longer PFS, and among the 
HRQoL variables only less nausea and vomiting was prognostic for longer PFS. Results of this subgroup 
analysis also showed a small added value of the HRQoL variables compared to the clinical variables 
only; 1.8% for OS and 0.7% for PFS (Table 5). 
 
Discussion 
We studied the added value of baseline HRQoL as prognostic indicator for OS and PFS in a large, 
heterogeneous sample of glioma patients by pooling individual HRQoL and sociodemographic/clinical 
data from previously conducted RCTs, controlling for known prognostic factors. Although this sample 
represents a large proportion of the glioma patient population regarding sex, age and type of tumor, 
the patients included in our analysis had a relatively good performance status, indicating selection 
bias, likely driven by stringent inclusion criteria for RCTs26. Moreover, patients who completed a 
baseline form (86%) had a better OS and PFS than those who did not, reflecting a selection bias in the 
available sample of trial patients. 
The prognostic value of known clinical parameters was confirmed in this study; younger and 
female patients, those with a better performance status, a non-glioblastoma tumor type (irrespective 





treatment regimens than radiotherapy alone had both significantly longer OS and PFS. Of note, we did 
not include interaction effects, hampering estimation of survival for specific subgroups (e.g. 
glioblastoma patients who were treated with radiotherapy only). Nevertheless, several HRQoL 
parameters provided independent prognostic information in addition to the known clinical variables, 
confirming previous results in glioma patients8-10. Although the C-index scores indicated that adding 
HRQoL parameters to the prognostic model did improve the model, the added value was small (1.1% 
for OS and 0.7% for PFS). Overall, the predictive accuracy was reasonable for OS (C-index of .716), and 
slightly less accurate for PFS (c-index of .679). Because HRQoL added little prognostic information to 
the clinical variables, further validation and calibration of these models was not considered 
meaningful. 
Role and cognitive functioning were the only two HRQoL variables that were independently 
prognostic for both OS and PFS. Other studies including different types of glioma patients also found 
that baseline cognitive complaints, as measured with the EORTC QLQ-C30 cognitive functioning scale, 
or objective cognitive functioning measured with a neuropsychological test battery or the Mini-Mental 
State Examination (MMSE), were prognostic for OS8,9,27-31. Cognitive impairment might be an early 
indicator of tumor progression which may not (yet) be visible or detected on scans32. Another 
explanation could be that patients’ cognitive complaints act as a proxy for tumor volume, which was 
not included as a covariate in our study, but is associated with survival33. The finding that role 
functioning was an independent prognostic variable for OS did not replicate earlier brain tumor 
studies, but might be indicative of the impact of the disease on functioning in daily life. Indeed, role 
functioning was also found to be prognostic in, for example, testicular cancer patients, where the 
disease similarly strikes at a younger age compared to other cancers, affecting the working life of 
patients, and therefore the role functioning of these patients6. Other HRQoL variables that were 
prognostic in our study were motor dysfunction (for OS), nausea and vomiting and appetite loss (for 





In the two subgroup analyses including AEDs and corticosteroid use or the molecular markers, 
all known clinical variables remained prognostic for OS and PFS. In contrast, the HRQoL variables 
varied across subgroups: other functioning scales and symptoms were of prognostic value in the 
subgroup models when compared to the ‘original model’. Moreover, some HRQoL variables were 
unexpectedly prognostic for PFS and OS, i.e. more appetite loss for prolonged PFS in the main analysis 
and worse emotional functioning for prolonged OS in the subanalysis including the molecular markers. 
These findings imply that although the clinical variables appeared to be robust prognostic markers, 
the prognostic value of the HRQoL variables depended on the subgroup of patients included. For the 
subgroup analysis including the molecular markers, assessment period may also be a factor, as the 
patients for whom data on molecular markers were available were included in more recent RCTs. We 
also considered using the HRQoL summary score34 instead of all individual scales/items, however, the 
summary score consists of items of the EORTC QLQ-C30 only, and does not include the brain tumor 
specific items/scales included in the EORTC QLQ-BN20. Taken together, our results suggest that the 
role of HRQoL data in predicting prognosis is limited, and not useful for stratification in future clinical 
trials, as it is unclear which variables should be assessed and included. 
Although the added prognostic value of HRQoL was small, HRQoL remains an important 
outcome in both clinical trials and practice. In clinical trials, HRQoL assessment is important to 
determine the net clinical benefit of a new treatment strategy35. In clinical practice, HRQoL 
assessments are important in monitoring patients’ functioning over time, and in informing patients 
and clinicians about the effect of the tumor and treatment on symptoms, functioning and quality of 
life. In addition, rather than baseline HRQoL data, a change in HRQoL from baseline during treatment, 
reflecting the impact of treatment on HRQoL, may be of more prognostic value, and should be further 
investigated to inform patients in clinical practice on the impact of treatment36.  
In conclusion, this study investigated the added prognostic value of HRQoL to the known 





parameters were independently prognostic for survival, the added value of baseline HRQoL to the 
known clinical prognostic variables was small. Thus, although HRQoL has proven to be an important 
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Table 1. Baseline sociodemographic and clinical characteristics of the patients included in the RCTs, 






HRQoL absent  
n=867 
P-value  
n (%) n (%) n (%) 
Sex 
     Male 
     Female 














Age (mean, SD) 53 (13) 53 (13) 55 (13) <.001* 
Histology 
     Non-glioblastoma 












     Newly diagnosed 












     WHO 0 
     WHO 1 
     WHO 2 


















     RT alone 
     Chemo alone 
     Angio alone 
     RT and chemo 
     RT and chemo and angio 
     Chemo and angio 
     TTF alone 
     Chemo and TTFields 

































     Resected  
     Not resected 














Use of AEDs 
     No 
     Yes 














Use of steroids 
     No 
     Yes 















     IDH-mutant 


















































WHO PS, World Health Organisation Performance Status; Trt, allocated treatment; RT, 
radiotherapy; chemo, chemotherapy; Angio, angiogenesis inhibitor; TTF, tumor-treating fields; 
HRQoL, health-Related Quality of Life; IDH, isocitrate dehydrogenase mutations; MGMT, O6-







Table 2. Univariable results of Cox proportional hazard models for overall and progression-free 
survival for the clinical variables and health-related quality of life parameters 
 Overall survival (OS) Progression-free survival (PFS) 
HR death (95% CI)a P-
value 

























WHO PS 0 (ref) 
WHO PS 1 

































Trt: RT alone (ref) 
Trt: Chemo alone 
Trt: Angio alone 
Trt: RT and chemo 
Trt: RT and chemo and angio 
Trt: Chemo and angio 
Trt: TTF alone 

































HRQoL – QLQ-C30  
Global Health status c .991 (.989-.992) <.001* .995 (.993-.996) <.001* 
Physical functioning c .989 (.987-.990) <.001* .993 (.991-.994) <.001* 
Role functioning c .994 (.993-.995) <.001* .997 (.996-.998) <.001* 
Emotional functioning c .997 (.995-.998) <.001* 1.000 (.999-1.001) .793 
Cognitive functioning c .992 (.991-.994) <.001* .996 (.994-.997) <.001* 
Social functioning c .996 (.995-.998) <.001* .998 (.997-1.000) .004* 
Fatigue c 1.006 (1.005-1.008) <.001* 1.004 (1.002-1.005) <.001* 
Nausea and vomiting c 1.004 (1.001-1.007) .006* 1.005 (1.002-1.007) <.001* 
Pain c 1.000 (.999-1.002) .739 .999 (.998-1.001) .257 
Dyspnea c 1.002 (1.001-1.004) .006* 1.001 (1.000-1.003) .097 
Insomnia c 1.000 (.999-1.001) .651 1.000 (.998-1.001) .420 
Appetite loss c 1.002 (1.001-1.004) .006* 1.002 (1.001-1.004) .004* 
Constipation c 1.002 (1.001-1.003) .004* 1.002 (1.001-1.003) .004* 
Financial difficulties c .999 (.997-1.000) .015* .998 (.997-.999) .002* 
Diarrhea c 1.000 (.998-1.003) .765 .999 (.997-1.001) .235 
HRQoL – QLQ-BN20 





Visual disorder c 1.006 (1.004-1.008) <.001* 1.005 (1.003-1.006) <.001* 
Motor dysfunction c 1.010 (1.009-1.012) <.001* 1.006 (1.005-1.008) <.001* 
Communication deficit c 1.006 (1.005-1.007) <.001* 1.004 (1.003-1.005) <.001* 
Headache c .999 (.998-1.001) .352 .999 (.998-1.000) .103 
Seizures c 1.001 (.999-1.003) .270 .999 (.998-1.001) .437 
Drowsiness c 1.002 (1.002-1.005) <.001* 1.003 (1.002-1.004) <.001* 
Hair loss c .998 (.997-1.000) .027* .999 (.998-1.001) .301 
Itchy skin c .999 (.997-1.001) .224 .999 (.998-1.001) .355 
Weakness of legs c 1.006 (1.005-1.008) <.001* 1.003 (1.002-1.004) <.001* 
Bladder control c 1.006 (1.005-1.008) <.001* 1.003 (1.002-1.005) <.001* 
OS, overall survival; PFS, progression free survival; HR, Hazard ratio; CI, confidence interval; WHO 
PS, World Health Organisation Performance Status; Trt, allocated treatment; RT, radiotherapy; 
chemo, chemotherapy; Angio, angiogenesis inhibitor; TTF, tumor-treating fields; HRQoL QLQ-C-30, 
health-related quality of life questionnaire QOL-C30; HRQoL – QLQ-BN20, health-related quality of 
life questionnaire brain tumor module; c continues variable; *statistically significant. 
a HRs reflect the probability for the event: death in case of OS and progression in case of PFS. HRs 
of >1 suggest and increased risk of death/progression compared to the reference category, HRs <1 








Table 3. Multivariable Cox proportional hazard models for overall survival, one including clinical 




 Cox model for clinical data 
 
Cox model for clinical and 
HRQOL data 
HR death (95% 
CI)a 























WHO PS 0 (ref) 
WHO PS 1 























Trt: RT alone (ref) 
Trt: Chemo alone 
Trt: Angio alone 
Trt: RT and chemo 
Trt: RT and chemo and angio 
Trt: Chemo and angio 
Trt: TTF alone 


































Role functioningc - - .99 (.99-.99) .037* 
Cognitive functioningc - - .99 (.99-.99) .002* 
Motor dysfynctionc - - 1.00 (1.00-1.01) .026* 
HR, Hazard ratio; CI, confidence interval; WHO PS, World Health Organisation Performance Status; 
Trt, allocated treatment; RT, radiotherapy; chemo, chemotherapy; Angio, angiogenesis inhibitor; 
TTF, tumor-treating fields; HRQoL, health-related quality of life; ref, reference group in analysis; a 
significant HRQoL variables are presented; c continues variable; * statistically significant. 
Models are stratified for disease stage (newly diagnosed/recurrent). 
a HRs reflect the probability for the event death. HRs of >1 suggest and increased risk of death 





Table 4. Multivariable Cox proportional hazard models for progression-free survival, one including 
clinical data only, and one model including both clinical and HRQoL data  
 Cox model for clinical data 
 
Cox model for clinical and 
HRQOL data 
HR progression 
(95% CI) a 
P-valuea HR progression 
























WHO PS 0 (ref) 
WHO PS 1 























Trt: RT alone (ref) 
Trt: Chemo alone 
Trt: Angio alone 
Trt: RT and chemo 
Trt: RT and chemo and angio 
Trt: Chemo and angio 
Trt: TTF alone 


































Role functioningc - - .99 (.99-.99) .010* 
Cognitive functioningc - - .99 (.99-.99) .032* 
Nausea and Vomitingc - - 1.00 (1.00-1.01) .010* 
Appetite lossc - - .99 (.99-.99) .011* 
HR, Hazard ratio; CI, confidence interval; WHO PS, World Health Organisation Performance Status; 
Trt, allocated treatment; RT, radiotherapy; chemo, chemotherapy; Angio, angiogenesis inhibitor; 
TTF, tumor-treating fields; HRQoL, health-related quality of life; Ref, reference group in analysis; a 
significant HRQoL variables are presented; c continues variable; * statistically significant. 
Models are stratified for disease stage (newly diagnosed/recurrent). 
a HRs reflect the probability for the event progression. HRs of >1 suggest and increased risk of 







Table 5. Performance and internal validation of the multivariable Cox proportional hazard models 












OS: clinical model 4944 .7172 .7157 .002 - 
OS: clinical + HRQoL model 4396 .7254 .7213 .004 1.1% 
PFS: clinical model 5018 .6805 .6793 .001 - 
PFS: clinical + HRQoL model 4458 .6863 .6828 .004 0.7 % 
Sub analysis 
OS: clinical model + AEDs, steroids 2292 .7069 .7028 .004 - 
OS: clinical + HRQoL model + AEDs,  2069 .7166 .7054 .011 0.5% 
 steroids      
PFS: clinical model + AEDs, steroids 2321 .7058 .7032 .003 - 
PFS: clinical + HRQoL model + AEDs,  2093 .7099 .7021 .008 -.2% 
 steroids      
OS: WHO 2016 classification +  1748 .6962 .6877 .009 - 
 MGMT: clinical model      
OS: WHO 2016 classification +  1503 .7142 .6970 .017 1.8% 
 MGMT: clinical + HRQoL model      
PFS: WHO 2016 classification +  1765 .6865 .6800 .007 - 
 MGMT: clinical model      
PFS: WHO 2016 classification +  1518 .6979 .6835 .014 0.7% 
 MGMT: clinical + HRQoL model      
OS, overall survival; PFS, progression free survival; AEDs, anti-epileptic drugs; HRQoL, health-related 
quality of life; WHO, World Health Organisation; a measure of internal validation: c-index minus the 
bootstrapped c-index; b added value of the bootstrapped c-index of the clinical + HRQoL model 
compared to the clinical mode. The added value is calculated using the formula: ((clinical+HRQoL 





Supplementary Table 1. Included RCTs 
Included RCTs Patient population Study sample 
size of RCT 
ref 
EORTC 26951 Newly diagnosed anaplastic 
oligodendroglioma 
292 1 
EORTC 22981-26981 Newly diagnosed glioblastoma 573 2 
EORTC 26071 (CENTRIC) Newly diagnosed glioblastoma MGMT 
methylated 
504 3 
EORTC 22033-26033 Newly diagnosed and recurrent low-
grade glioma 
700 4 
EORTC 26101 Recurrent glioblastoma 592 5 
EORTC 26091 (TAVAREC) Recurrent grade II and III gliomas 155 6 
EORTC 26053-22054 (CATNON) non-1p/191 deleted anaplastic glioma 745 7 
NOA-08 Grade III and IV astrocytoma in elderly 373 8 
NORDIC Newly diagnosed glioblastoma in 
elderly 
342 9 
ANOCEF Newly diagnosed glioblastoma in 
elderly 
81 10 
BELOB Recurrent glioblastoma 148 11 
AVAGLIO Newly diagnosed glioblastoma 921 12 
GLARIUS Newly diagnosed MGMT-non 
methylated glioblastoma  
170 13 
EF-11 Recurrent glioblastoma  237 14 







Supplementary Table 2. Subgroup analysis: Multivariable Cox proportional hazard models for 
overall survival and progression-free survival including clinical and HRQoL data, and anti-epileptic 
drug and steroid use 
 Overall survival (OS) Progression-free survival (PFS) 

























WHO PS 0 (ref) 
WHO PS 1 













Trt: RT alone 
Trt: Chemo alone 
Trt: Angio alone 
Trt: RT and chemo 
Trt: RT and chemo and angio 
Trt: Chemo and angio 
Trt: TTF alone 

































Steroids use: no (ref) 










Fatiguec 1.0 (1.0-1.0) .023* NS NS 
Motor dysfunctionc 1.0 (1.0-1.0) <.001* NS NS 
Role functioningc NS NS .99 (.99-.99) .009* 
Appetite lossc NS NS .10 (.10-.10) .003* 
Weakness of the legsc NS NS .10 (.10-.10) .034* 
HR, Hazard ratio; CI, confidence interval; WHO PS, World Health Organisation Performance Status; 
Trt, allocated treatment; RT, radiotherapy; chemo, chemotherapy; Angio, angiogenesis inhibitor; 
TTF, tumor-treating fields; HRQoL, health-related quality of life; Ref, reference group in analysis; a 
significant HRQoL variables are presented; c continues variable; * statistically significant; NS, non-
significant; Models are stratified for disease stage (newly diagnosed/recurrent). 
a HRs reflect the probability for the event: death in case of OS and progression in case of PFS. HRs 
of >1 suggest and increased risk of death/progression compared to the reference category, HRs <1 







Supplementary Table 3. Subgroup analysis: Multivariable Cox proportional hazard models for 
overall survival and progression-free survival including clinical and HRQoL data, with tumor 
classification based on the WHO 2016 classification criteria 
 Overall survival (OS) Progression-free survival 
(PFS) 















Agec 1.02 (1.02-1.03) <.001* 1.01 (1.00-1.01) .019* 
Diffuse Astrocytoma IDH-mutant (ref) ref   ref   
Diffuse astrocytoma IDH-wildtype 2.18 (.30-15.69) .383 1.60 (.94—2.72) .084 
Diffuse astrocytoma NOS 3.30 (.46-23.50) .233 1.41 (.83-2.43) .203 
Anaplastic astrocytoma IDH-mutant 2.04 (.46-8.98) .348 .43 (.24-.76) .004* 
Anaplastic astrocytoma IDH-wildtype 6.28 (1.46-27.08) .014* 2.16 (1.33-3.51) .002* 
Anaplastic astrocytoma NOS 2.94 (.69-12.53) .145 .86 (.55-1.35) .511 
Glioblastoma IDH-mutant 5.35 (1.21-23.70) .027* 2.53 (1.51-4.23) <.001* 
Glioblastoma IDH-wildtype 12.29 (2.98-.50.65) .001* 4.29 (2.92-6.29) <.001* 
Glioblastoma NOS 9.23 (2.22-38.40) .002* 3.53 (2.34-5.32) <.001* 
Oligodendroglioma IDH mutant and .00 (.00-4.4E71) .918 .88 (.54-1.45) .623 
 p19q-codeleted     
Oligodendroglioma NOS .00 (.00-1.4E101) .938 1.37 (.81-2.32) .239 
Oligoastrocytoma NOS .52 (.05-5.79) .597 1.03 (.69-1.52) .904 
Anaplastic oligoastrocytoma NOS 4.24 (1.02-17.72) .048* 1.23 (.84-1.82) .288 
WHO PS 0 (ref) 
WHO PS 1 























Trt: RT alone (ref) 
Trt: Chemo alone 
Trt: Angio alone 
Trt: RT and chemo 
Trt: RT and chemo and angio 
Trt: Chemo and angio 













































Emotional functioningc 1.00 (1.00-1.01) .024* NS NS 
Fatiguec 1.01 (1.00-1.01) .002* NS NS 





OS, overall survival; PFS, progression free survival; HR, Hazard ratio; CI, confidence interval; WHO 
PS, World Health Organisation Performance Status; Trt, allocated treatment; RT, radiotherapy; 
chemo, chemotherapy; angio, angiogenesis inhibitor; TTF, tumor-treating fields; HRQoL, health-
related quality of life; Ref, reference group in analysis; a significant HRQoL variables are presented; 
c continues variable; * statistically significant; NS, non-significant; Models are stratified for disease 
stage (newly diagnosed/recurrent). 
a HRs reflect the probability for the event: death in case of OS and progression in case of PFS. HRs 
of >1 suggest and increased risk of death/progression compared to the reference category, HRs <1 
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